GVR Report cover Erectile Dysfunction Drugs Market Size, Share & Trends Report

Erectile Dysfunction Drugs Market Size, Share & Trends Analysis Report By Product (Viagra, Cialis, Zydena, Levitra, Stendra, Others), By Region (North America, Europe, APAC, Latin America, MEA), And Segment Forecasts, 2023 - 2030

  • Report ID: 978-1-68038-604-2
  • Number of Pages: 79
  • Format: Electronic (PDF)
  • Historical Range: 2018 - 2021
  • Industry: Healthcare

Erectile Dysfunction Drugs Market Trends

The global erectile dysfunction drugs market size was valued at USD 2.46 billion in 2022 and is anticipated to grow at a compound annual growth rate (CAGR) of 8.8% from 2023 to 2030. There is a growing demand for erectile dysfunction (ED) drugs owing to the adoption of a sedentary lifestyle, associated stress, the increasing geriatric population, and the correlation between erectile dysfunction and diabetes, heart disease, and other chronic conditions. According to the Clinical Epidemiology and Global Health Journal, ED affects more than 150 million men globally, and by 2025, that number is predicted to rise to 322 million. The primary risk factor for the onset of ED is type 2 diabetes mellitus (T2DM), and diabetic men are three times more likely to develop ED than men without the disease.

U.S. erectile dysfunction drugs Market size and growth rate, 2023 - 2030

The likelihood of experiencing ED increases with age. According to a study published in the Journal of Clinical Medicine, men over 65 years of age have a 56% higher frequency of mild or total ED than men aged 40 to 44 years. Lifestyle choices such as smoking, excessive drinking, and recreational drug use negatively impact sexual functioning in men. Additional psychological factors such as stress, anxiety, depression, and interpersonal issues can impact normal erectile function.

A lifetime ED episode was experienced by around 35-75% of male diabetic patients, according to the WHO. As of 2021, the majority of the 422 million diabetic patients globally lived in low- and middle-income nations. However, the market growth could be hampered by a lack of healthcare infrastructure and manufacturing issues. For instance, Sun Pharmaceutical Industries Ltd. announced the recall of its generic drug Tadalafil in November 2021 due to a production fault. Such recalls leave a small gap in the supply of generic drugs for erectile dysfunction patients.

The COVID-19 pandemic positively impacted the sales of erectile dysfunction drugs, owing to their increased demand. As per the University of Pittsburgh School of Medicine, there was a high growth in the sales of erectile dysfunction drugs due to government-imposed lockdowns in 2020. Among all ED drugs, Cialis (Tadalafil) witnessed significant demand in the U.S. Other factors, such as easy access to ED drugs, support their market growth. Currently, various drugs are consumed to manage erectile dysfunction, including sildenafil (Revatio, Viagra), vardenafil (Levitra, Staxyn ODT), tadalafil (Adcirca, Cialis), and avanafil (Stendra), among others.

Product Insights

The Viagra segment held the dominant revenue share of over 55% in 2022. Companies are undertaking strategic initiatives such as research collaborations, partnerships, and agreements to expand their business footprint. For instance, in January 2020, Pfizer’s Greenstone and Digital Men’s Health Clinic Roman signed an agreement to provide a generic version of Viagra to Roman members. Such developments help boost segment growth. In another instance, in June 2023, Futura Medical’s topical gel product named Eroxon received FDA approval for its OTC marketing in the U.S.

The others segment is expected to expand at a lucrative CAGR of 13.3% over the forecast period, owing to the large application base and availability of ED medicines such as Helleva (lodenafil carbonate), Mvix (mirodenafil), and others, used to treat adult patients with erectile dysfunction. Increasing approval of over-the-counter ED products offers easy access to ED patients. For instance, in February 2022, Adamed became the first Polish company to receive marketing authorization for Tadalafil MAXON in the OTC category. Thus, the introduction of such products boosts the utilization of ED drugs.

Regional Insights

North America dominated the erectile dysfunction drugs market and accounted for a revenue share of 51.3% in 2022, due to the high burden of disease, strong healthcare infrastructure, and rapid approval of new products for treatment in the region. For instance, in March 2022, Lupin received FDA approval for its ANDA for sildenafil (10 mg/mL oral suspension) to market a generic equivalent of Viatris Specialty LLC’s Revatio for Oral Suspension. The accessibility of affordable generic products increases patient compliance, consequently increasing the consumer base and market revenue.

Global erectile dysfunction drugs Market share and size, 2022

On the other hand, Asia Pacific is expected to advance at the fastest CAGR of 10.2% during the forecast period. The growth of the region is attributable to the frequent entry of new products into the market. For instance, in May 2020, iX Biopharma announced the supply of Silcap and Wafesil through telemedicine in Australia for the treatment of adult patients with erectile dysfunction. According to a study published by the National Library of Medicine, the prevalence of ED in Asia varies between 9% and 73%, offering opportunities for significant market expansion in the region.

Key Companies & Market Share Insights

Major players are adopting strategies such as mergers and acquisitions for regional expansion to grab a greater market share. For instance, in May 2022, the Spanish specialty pharmaceutical company Laboratorios Rubio S.A. sold its Bandol prescription brand to Aspargo Laboratories, Inc. Some of the prominent players in the global erectile dysfunction drugs market include:

  • Pfizer Inc.

  • Eli Lilly and Company

  • Teva Pharmaceutical Industries Ltd.

  • Sanofi

  • Sun Pharmaceutical Industries Ltd.

  • Bayer AG

  • Petros Pharmaceuticals, Inc.

  • VIVUS, Inc.

  • Auxilium Pharmaceuticals, Inc.

  • Adamed

  • Cipla Inc.

Erectile Dysfunction Drugs Market Report Scope

Report Attribute


Market size value in 2023

USD 2.65 billion

Revenue forecast in 2030

USD 4.79 billion

Growth rate

CAGR of 8.8% from 2023 to 2030

Base year for estimation


Historical data

2018 - 2021

Forecast period

2023 - 2030

Quantitative units

Revenue in USD million and CAGR from 2022 to 2030

Reports updated

October 2023

Report coverage

Revenue forecast, company ranking, competitive landscape, growth factors, and trends

Segments covered

Product, region

Regional scope

North America; Europe; Asia Pacific; Latin America; MEA

Country scope

U.S.; Canada; UK; Germany; France; Spain; Italy; Sweden; Norway; Denmark; China; Japan; India; Australia; South Korea; Thailand; Brazil; Mexico; Argentina; South Africa; Saudi Arabia; UAE; Kuwait

Key companies profiled

Pfizer, Inc.; Eli Lilly and Company; Teva Pharmaceutical Industries Ltd.; Sanofi; Sun Pharmaceutical Industries Ltd.; Bayer AG; Petros Pharmaceuticals, Inc.; VIVUS, Inc.; Auxilium Pharmaceuticals, Inc.; Adamed; Cipla Inc.

Customization scope

Free report customization (equivalent up to 8 analyst’s working days) with purchase. Addition or alteration to country, regional, and segment scope.

Pricing and purchase options

Avail customized purchase options to meet your exact research needs. Explore purchase options


Global Erectile Dysfunction Drugs Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For the purpose of this study, Grand View Research has segmented the global erectile dysfunction drugs market report on the basis of product and region:

Global erectile dysfunction drugs Market Report Segmentation

  • Product Outlook (Revenue, USD Million, 2018 - 2030)

    • Viagra

    • Cialis

    • Zydena

    • Levitra

    • Stendra

    • Others

  • Regional Outlook (Revenue, USD Million, 2018 - 2030)

    • North America

      • U.S.

      • Canada

    • Europe

      • UK

      • Germany

      • France

      • Italy

      • Spain

      • Sweden

      • Norway

      • Denmark

    • Asia Pacific

      • China

      • Japan

      • India

      • Australia

      • Thailand

      • South Korea

    • Latin America

      • Brazil

      • Mexico

      • Argentina

    • Middle East and Africa

      • Saudi Arabia

      • South Africa

      • UAE

      • Kuwait

Frequently Asked Questions About This Report

gvr icn


gvr icn

This FREE sample includes data points, ranging from trend analyses to estimates and forecasts. See for yourself.

gvr icn


We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities. Contact us now

Certified Icon

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.